Several lines of evidence have underlined the role of PTEN loss on melanoma progression and resistance to immunotherapy management in patients sequentially treated with anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and anti PD-1 [63] agents. The gene discussed is PTEN; the disease is melanoma.